医学
临床试验
概化理论
标准化
代理(哲学)
包裹体(矿物)
家庭医学
批准的药物
病理
药品
精神科
哲学
社会学
认识论
法学
性别研究
统计
数学
政治学
作者
David E. Gerber,Harpreet Singh,Erin Larkins,Andrea Ferris,Patrick M. Forde,Wendy Selig,Upal Roy
出处
期刊:JAMA Oncology
[American Medical Association]
日期:2022-08-04
卷期号:8 (9): 1333-1333
被引量:19
标识
DOI:10.1001/jamaoncol.2022.1664
摘要
As an initial step, the recommended cross-trial standardization of eligibility criteria may harmonize trial populations. Going forward, by connecting diverse stakeholders and providing formal opportunity for public input, the emerging FDA draft guidance may also provide an opportunity to revise and simplify long-standing approaches to trial eligibility. This work serves as a prototype for similar efforts now underway for other cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI